silver atom (CAS 54-85-3)

这就是贵公司的产品在自己欧洲网店里的样子
页面、名称、CAS 号、技术信息 —— 都已经就位。
现在只差 3 样,全部与贵公司自己的资料有关。
我们已经做好 产品页面 · 英文名称 · CAS 号 · 技术数据 · 欧盟合规信息框架
纯度 AR · 包装规格 250g —— 这些我们已经从贵公司的公开目录整理出来了
需要贵公司提供,只有 3 样 1. 贵公司的商标(logo)
2. 公司名称与注册地址
3. 每种规格的价格
收到这四样之后会发生什么

现在这份安全数据表和产品标签上印的,是 MolGod 的名称和地址。 这是因为贵公司的资料我们还没有 —— 我们不会替贵公司编造。

收到之后,我们把它们全部换成贵公司的
安全数据表、产品标签、产品页面、报价单、发票 —— 从头到尾都是贵公司的品牌, 不会出现我们的名字。

贵公司拿到的是一个可以直接开始卖货的网店,不是一份演示文件。

适用范围:仅限欧盟市场

我们编制的安全数据表依据的是欧盟法规—— (EC) No 1907/2006(REACH)附件 II 及 (EU) 2020/878。

中文版本是从欧盟版本翻译而来的,仅供参考。 它不是中国市场上具有法律效力的文件,不能用于在中国境内的 申报、备案、运输或流通。

中国市场的安全数据表须按 GB/T 16483GB/T 17519 另行编制, 这不在本次交付范围内。贵公司在中国境内的合规文件,仍由贵公司自行负责。

我们是做网店的公司,不是化工公司。
不买货、不存货、不发货、不碰贵公司的客户、不从货款抽成。 货、客户、价格、订单、收款、发货 —— 全部在贵公司手里。
← 返回贵公司的全部产品

silver atom. CAS 54-85-3. 250g.

We are not issuing this sheet yet.

Our engine could not build a document for this substance that meets our own completeness threshold, so it is held for review rather than published. We would rather tell you that than sell you a sheet we do not stand behind.

Leave your details and we will tell you when it is ready, or what we can issue in the meantime.

Get the full details for CAS 54-85-3

Sixteen sections in the structure of REACH Annex II, the harmonised classification, and the source behind every value — issued in one language you choose.

A sheet that fails inspection stops the shipment, not the paperwork.

Tell us where to send it. We reply within one working day.

We reply within one working day.

Working draft €49.99 · expert-reviewed €249.99, per substance.

What is in the buyer pack

Everything your compliance officer will ask for, in one file.

  • The product page as PDF — the record as published, so what you forward matches what you read.
  • The safety data sheet at your entitlement level — sixteen sections in the order set by REACH Annex II, for this substance, in the language you select.
  • The CLP label artwork — generated from the same classification as the sheet, so the two cannot disagree.
  • The specification, and the certificate of analysis where batch data exists.
  • sources.txt — every citation with the date it was read.
  • An explicit list of what we could not establish — fields marked unavailable rather than filled with an estimate. This is the honest part of the document and we do not hide it in a footnote.

Your European buyer is going to forward this to somebody who was not on the call. The pack exists so that what they forward is complete, self-explanatory and traceable — rather than four attachments and a sentence beginning “I think this is everything”.

These switch the language of this page. Single substances. Mixtures on enquiry. One document, one language — additional languages are priced separately. Every version, including the Chinese one, is written to EU law — (EC) No 1907/2006 (REACH) Annex II and (EU) 2020/878 — and translated from it. The Chinese version is a reference translation, not a legally valid document for the Chinese market: an SDS for China must be compiled separately to GB/T 16483 and GB/T 17519.

Données transcrites à partir de registres réglementaires et de la littérature spécialisée, avec indication de la source et de l'édition. Elles ne remplacent pas la fiche de données de sécurité du fournisseur. Les champs sans source enregistrée sont signalés comme tels.

Aperçu chimique: Isoniazid
Formule bruteC6H7N3O
Masse moléculaire137.14 g/mol
LogP (lipophilie)-0.7
Nom IUPACpyridine-4-carbohydrazide
SMILESC1=CN=CC=C1C(=O)NN
InChIKeyQRXWMOHMRWLFEY-UHFFFAOYSA-N

Synonymes: isoniazid · 54-85-3 · Isonicotinic acid hydrazide · Isonicotinohydrazide · pyridine-4-carbohydrazide

Sources de données : PubChem (NLM/NIH)
Dernière mise à jour : 2026-09-03

RECHERCHE SCIENTIFIQUE

[1]PubMed2026
Martinez L, Campbell JI, Linde L et al.. (2026). "The effectiveness of isoniazid preventive treatment among contacts of multidrug-resistant tuberculosis: a systematic review and individual-participant
[2]PubMed2025
Wang ER, Cho K, Harrison GA et al.. (2025). "Metabolic rewiring of isoniazid sensitivity in Mycobacterium tuberculosis.". Proceedings of the National Academy of Sciences of the United States of Americ
[3]PubMed2025
Ruan QL, Yang QL, Ma CL et al.. (2025). "Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pil
[4]PubMed2025
Wang D, Wang S, Jin Z et al.. (2025). "Tet2 Protects Against Isoniazid-Induced Hepatotoxicity via Regulating Autophagy.". FASEB journal : official publication of the Federation of American Societies f
[5]PubMed2024
Baral T, M SS, Thomas L et al.. (2024). "Isoniazid-induced pancreatitis: A systematic review.". Tuberculosis (Edinburgh, Scotland). https://doi.org/10.1016/j.tube.2024.102535
[6]PubMed2024
Perumal R, Naidoo K. (2024). "Are We Capable of Unveiling the Missed Epidemic of Isoniazid-resistant Tuberculosis?". Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.202407-7
[7]PubMed2024
Huang HL, Lee MR, Lee CH et al.. (2024). "One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Po
[8]Europe PMC2002
et al.. (2002). "NIEHS Technical Report on the 13-Week Toxicity Study of 3′-Azido-3′-deoxythymidine (AZT) and Isoniazid Combinations (CAS Nos. 30516-87-1 and 54-85-3) Administered by Gavage to B6C3F1
📚 Références scientifiques (Chicago Author-Date) 9 refs · 2 baz

MOLECULE Bibliographie par CAS (en direct depuis 13+ bases de données)

Sources : db:pubmed (7) · db:Europe PMC (2)

  1. db:pubmed Martinez L, Campbell JI, Linde L et al.. (2026). "The effectiveness of isoniazid preventive treatment among contacts of multidrug-resistant tuberculosis: a systematic review and individual-participant meta-analysis.". American journal of respiratory and critical care medicine. https://doi.org/10.1164/rccm.202411-2340OC
  2. db:pubmed Wang ER, Cho K, Harrison GA et al.. (2025). "Metabolic rewiring of isoniazid sensitivity in Mycobacterium tuberculosis.". Proceedings of the National Academy of Sciences of the United States of America. https://doi.org/10.1073/pnas.2421336122
  3. db:pubmed Ruan QL, Yang QL, Ma CL et al.. (2025). "Efficacy and safety of a novel short course rifapentine and isoniazid regimen for the preventive treatment of tuberculosis in Chinese silicosis patients: a pilot study (SCRIPT-TB).". Emerging microbes & infections. https://doi.org/10.1080/22221751.2025.2502010
  4. db:pubmed Wang D, Wang S, Jin Z et al.. (2025). "Tet2 Protects Against Isoniazid-Induced Hepatotoxicity via Regulating Autophagy.". FASEB journal : official publication of the Federation of American Societies for Experimental Biology. https://doi.org/10.1096/fj.202500245R
  5. db:pubmed Baral T, M SS, Thomas L et al.. (2024). "Isoniazid-induced pancreatitis: A systematic review.". Tuberculosis (Edinburgh, Scotland). https://doi.org/10.1016/j.tube.2024.102535
  6. db:pubmed Perumal R, Naidoo K. (2024). "Are We Capable of Unveiling the Missed Epidemic of Isoniazid-resistant Tuberculosis?". Annals of the American Thoracic Society. https://doi.org/10.1513/AnnalsATS.202407-772ED
  7. db:pubmed Huang HL, Lee MR, Lee CH et al.. (2024). "One-month daily and three-month weekly rifapentine plus isoniazid are comparable in completion rate and safety for latent tuberculosis infection in non-HIV Population: a randomized controlled trial.". Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases. https://doi.org/10.1016/j.cmi.2024.06.024
  8. db:Europe PMC et al.. (2002). "NIEHS Technical Report on the 13-Week Toxicity Study of 3′-Azido-3′-deoxythymidine (AZT) and Isoniazid Combinations (CAS Nos. 30516-87-1 and 54-85-3) Administered by Gavage to B6C3F1 Mice".
  9. db:Europe PMC et al.. (1999). "NIEHS Technical Report on the Reproductive, Developmental, and General Toxicity Study of 3′-Azido-3′-Deoxythymidine (AZT) and Isoniazid Combinations (CAS Nos. 30516-87-1 and 54-85-3) Administered by Gavage to Swiss (CD-1®) Mice".
Statut réglementaire de la substance
Aucune entrée pour ce CAS dans les listes de restrictions vérifiées (liste candidate SVHC, REACH Annexe XVII ; ensembles de données incomplets - il ne s'agit pas d'une confirmation de conformité). Classification CLP et statut de transport (ADR) : voir la section GHS et la fiche de données de sécurité (SDS).
🧪 Données chimiques
Numéro CAS
54-85-3
Formule brute
C6H7N3O
Masse molaire
137.14 g/mol
Nom IUPAC (EN)
pyridine-4-carbohydrazide
SMILES
C1=CN=CC=C1C(=O)NN
InChIKey
QRXWMOHMRWLFEY-UHFFFAOYSA-N
🔍 Identifiants externes
13 sur 16 systèmes d'ID81%
Base de donnéesIdentifiantActions
CAS Registry Number54-85-3Ouvrir →
PubChem CID3767[1]Ouvrir →
InChIKeyQRXWMOHMRWLFEY-UHFFFAOYSA-N[1]Ouvrir →
SMILESC1=CN=CC=C1C(=O)NN[1]
EC Number200-214-6[2]Ouvrir →
DrugBankDB00951Ouvrir →
KEGG CompoundD00346Ouvrir →
HMDBHMDB0015086Ouvrir →
ChemSpider3635[3]Ouvrir →
MeSH UID (NLM)D007538Ouvrir →
UNII (FDA)V83O1VOZ8LOuvrir →
NSC Number (NCI)9659Ouvrir →
WikiData QIDQ423169Ouvrir →

Sources : PubChem (NIH), Wikidata SPARQL, KEGG, ChEMBL (EBI), CompTox CTX (EPA).

📚 Références scientifiques (Chicago Author-Date) (3 sources)
  1. PubChem. National Center for Biotechnology Information (NIH/NLM), chemical compound database. dotyczy: PubChem CID · InChIKey · SMILES
  2. ECHA. EC Inventory — EINECS, ELINCS, NLP and List Numbers assigned under REACH. Helsinki: European Chemicals Agency. dotyczy: EC Number
  3. ChemSpider. Royal Society of Chemistry, chemical structure database. dotyczy: ChemSpider

Why this page can be checked

Identity

CAS, EC and molecular formula, resolved across the identifier systems a buyer uses. The count of systems resolved is shown, so you can see how well characterised this substance is rather than assuming.

Data

Every physicochemical value carries the source it came from and the date that source was read. Open any of them.

Classification

Read against the harmonised entry where one exists, with the index number stated. Self-classification is shown separately and labelled.

Regulatory

Inventory, restriction, authorisation and candidate-list status, each stated individually. Where a status is not established, this page says so — it never says no restrictions apply.

Documentation

Which documents exist, at what review level, in which languages, and when each was issued.

Supplier

Who is selling this, and what they have published about themselves.

Nothing on this page is a certification. It is a record you can audit.

Two guarantees, both with their limits stated

The Gap Report Guarantee

If the available evidence cannot support a defensible document for your CAS number and product specification, we will not invent the missing values. You receive a documented gap report and choose: a refund, store credit, or the report on its own.

A visible gap is worth more than a plausible number, because the plausible number is the one that fails when somebody checks it.

The Re-issue Promise

If a signed card is rejected by an authority or by a customer’s compliance officer on one of the points we checked and reported as passed, we re-issue it corrected at no charge and credit the original fee.

This covers the checks we performed and named. It does not cover registration status, tonnage, or your role in the supply chain — those are not ours to hold, and a guarantee that pretended otherwise would be worth nothing.

silver atom — CAS 54-85-3, purity AR, 250g. Listed by Beijing Tong Guang. Prepared from the supplier’s public catalogue; not verified against their internal data.

Données de PubChemSource : PubChem (NIH)